Business
Theralase's Latest Scientific Research to be Presented at the 17th Annual International Photodynamic Association World Congress
Nine Scientific Papers Detailing the Latest Scientific Research of Theralase ® 's...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase's Latest Scientific Research to be Presented at the 17th Annual International Photodynamic Association World CongressNine Scientific Papers Detailing the Latest Scientific Research of Theralase®'s Anti-Cancer Technology (\"ACT\") Platform have been Peer Reviewed and will be Presented at the International Photodynamic Association World CongressTORONTO, ON / ACCESSWIRE / April 22, 2019 / Theralase® Technologies Inc. (\"Theralase®\" or the \"Company\") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (\"PDC\") and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce nine scientific papers pertaining to the Company's Anti-Cancer Technology (\"ACT\") Platform and Rutherrin® based Photo Dynamic Therapy (\"PDT\") have been peer reviewed and selected for presentation at the 17th Annual International Photodynamic Association (\"IPA\") World Congress, to be held in Cambridge, Massachusetts, USA from June 28th to July 4th, 2019.IPA has been bringing together researchers and clinicians in all fields of PDT and PhotoDiagnosis (\"PD\") since 1986. Every two years, the IPA organizes a conference to foster scientific development and contribute to clinical practice, ultimately capturing the current status of the field.The IPA World Congress celebrates the best and latest academic and clinical research in PDT. This year, the IPA World Congress has elected nine of Theralase®'s scientific research papers to be presented by Theralase® affiliated scientists and researchers demonstrating the growing interest in Theralase®'s cutting-edge research as it pertains to the treatment of cancer.Arkady Mandel MD, Ph.D., D.Sc., Chief Scientific Officer, Theralase® stated, \"Theralase® is delighted that its patented and patent-pending technologies will be presented and further validated at the IPA World Congress. This ground-breaking scientific research discusses Theralase®'s successes in its recently completed Phase Ib Non-Muscle Invasive Bladder Cancer (\"NMIBC\") clinical study and lays a strong foundation for further development of TLD-1433, and its formulation Rutherrin®, when combined with laser delivery technologies, in the tr...